scholarly journals Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease

2019 ◽  
Vol 12 (3) ◽  
pp. 240-246 ◽  
Author(s):  
Klaus Romero ◽  
Daniela Conrado ◽  
Jackson Burton ◽  
Timothy Nicholas ◽  
Vikram Sinha ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Dopamine Transporter ◽  
Early Parkinson’S Disease

Nigrostriatal dopamine transporter availability in early Parkinson's disease

2018 ◽  
Vol 33 (4) ◽  
pp. 592-599 ◽  
Author(s):  
Patrik Fazio ◽  
Per Svenningsson ◽  
Zsolt Cselényi ◽  
Christer Halldin ◽  
Lars Farde ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Transporter ◽  
Nigrostriatal Dopamine ◽  
Early Parkinson’S Disease

scholarly journals Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease

2019 ◽  
Vol 34 (10) ◽  
pp. 1505-1515 ◽  
Author(s):  
Gennaro Pagano ◽  
Flavia Niccolini ◽  
Heather Wilson ◽  
Tayyabah Yousaf ◽  
Naheed L. Khan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Transporter ◽  
Disease Burden ◽  
Phosphodiesterase 10A ◽  
Early Parkinson’S Disease

Key Clinical Trials in Pharmacological Treatment of Early Parkinson’s Disease

US Neurology ◽  
2009 ◽  
Vol 05 (01) ◽  
pp. 25
Author(s):  
Binit Shah ◽  
Tanya Simuni ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Pharmacological Treatment ◽  
Treatment Options ◽  
Motor Symptoms ◽  
Neuroprotective Agents ◽  
The Us ◽  
Non Motor Symptoms ◽  
Early Parkinson’S Disease

Parkinson’s disease (PD) is the second most common neurodegenerative disease and affects more than one million people in the US. The management of PD involves treatment of motor and non-motor symptoms of the disease. The armamentarium of treatment options for PD has increased substantially over the last 10 years. This article reviews recent clinical trials investigating efficacy, complications of treatment, and possible neuroprotective agents in patients with early PD.

scholarly journals Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes

Brain ◽  
2019 ◽  
Vol 142 (11) ◽  
pp. 3565-3579 ◽  
Author(s):  
Yaping Chu ◽  
Scott Muller ◽  
Adriana Tavares ◽  
Olivier Barret ◽  
David Alagille ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Transporter ◽  
Lewy Body ◽  
Alpha Synuclein ◽  
Lewy Body Pathology ◽  
Nigrostriatal Degeneration ◽  
Early Parkinson’S Disease

See Dehay and Bezard (doi:10.1093/brain/awz329) for a scientific commentary on this article. Intrastriatal injections of fibrillar α-synuclein in rodents have been shown to induce a Parkinson’s disease-like spreading of Lewy body pathology. Chu et al. inject exogenous α-synuclein pre-formed fibrils into the putamen of non-human primates, and observe spreading of pathology, nigrostriatal degeneration, and dopamine transporter upregulation indicative of early Parkinson’s disease.

Sign in / Sign up

Export Citation Format

Share Document